Evidence Hub

Candida auris in Europe: Epidemiology and antifungal resistance. A systematic review

Rodríguez-Cerdeira C, Martínez-Herrera E, Saunte DML, Vite-Garín T, Fuentes-Venado CE, Hay R, Zárate-Segura PB, Szepietowski J et al.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2026

886 participants

Abstract

Background: Candida auris is a widely distributed yeast that is considered a dangerous pathogen, with reported mortality rates ranging from 30% to 60%. This yeast shows a high level of resistance to several antifungal agents commonly used to treat systemic infections. The pathogen persists on contaminated surfaces, tolerates hospital-grade disinfectants, survives desiccation and spreads easily through direct or indirect contact. It has been reported on all five continents and is increasingly prevalent in Europe.

Objective: To determine the distribution and antifungal susceptibility/resistance of Candida auris isolates identified in Europe until January 2025.

Methods: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Searches were conducted in EBSCOhost, MEDLINE/PubMed, Scopus and SciELO databases using the terms 'Candida auris' and 'Candidozyma auris', combined with the name of each European country. It was limited to English or Spanish articles published until 31 January 2025, excluding reviews, meta-analyses and book chapters.

Results: Ninety-one articles reporting antifungal susceptibility were retrieved, covering 2191 clinical isolates of C. auris from 16 countries. Most isolates were from Spain (n = 886, 40.44%), Italy (n = 553, 25.24%), Greece (n = 214, 9.77%), the United Kingdom (n = 182, 8.31%) and Russia (n = 108, 4.93%), accounting for 88.68% of cases. The remaining 248 isolates (11.32%) were…

How strong is the evidence?

Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 886 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free